vs
AGENUS INC（AGEN）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是AGENUS INC的72.3倍（$2.5B vs $34.2M）。艾伯维净利率更高（35.5% vs -31.0%，领先66.5%）。艾伯维同比增速更快（83.2% vs 27.5%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
AGEN vs ARGX — 直观对比
营收规模更大
ARGX
是对方的72.3倍
$34.2M
营收增速更快
ARGX
高出55.8%
27.5%
净利率更高
ARGX
高出66.5%
-31.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $2.5B |
| 净利润 | $-10.6M | $877.2M |
| 毛利率 | — | 89.5% |
| 营业利润率 | 42.1% | 28.9% |
| 净利率 | -31.0% | 35.5% |
| 营收同比 | 27.5% | 83.2% |
| 净利润同比 | 77.3% | 1.3% |
| 每股收益（稀释后） | $0.09 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENARGX
| Q4 25 | $34.2M | $2.5B | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $25.7M | $1.8B | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $26.8M | $1.4B | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $23.5M | $901.9M | ||
| Q1 24 | $28.0M | — |
净利润AGENARGX
| Q4 25 | $-10.6M | $877.2M | ||
| Q3 25 | $63.9M | — | ||
| Q2 25 | $-30.0M | $414.8M | ||
| Q1 25 | $-26.4M | — | ||
| Q4 24 | $-46.8M | $865.6M | ||
| Q3 24 | $-67.2M | — | ||
| Q2 24 | $-54.8M | $-32.5M | ||
| Q1 24 | $-63.5M | — |
毛利率AGENARGX
| Q4 25 | — | 89.5% | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | 89.2% | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | 90.2% | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | 89.4% | ||
| Q1 24 | 99.6% | — |
营业利润率AGENARGX
| Q4 25 | 42.1% | 28.9% | ||
| Q3 25 | -15.0% | — | ||
| Q2 25 | -65.0% | 19.2% | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -96.5% | 8.7% | ||
| Q3 24 | -125.5% | — | ||
| Q2 24 | -128.4% | -15.4% | ||
| Q1 24 | -117.4% | — |
净利率AGENARGX
| Q4 25 | -31.0% | 35.5% | ||
| Q3 25 | 211.4% | — | ||
| Q2 25 | -116.8% | 23.4% | ||
| Q1 25 | -109.6% | — | ||
| Q4 24 | -174.4% | 64.1% | ||
| Q3 24 | -267.7% | — | ||
| Q2 24 | -233.1% | -3.6% | ||
| Q1 24 | -226.6% | — |
每股收益（稀释后）AGENARGX
| Q4 25 | $0.09 | $13.25 | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $-1.00 | $6.32 | ||
| Q1 25 | $-1.03 | — | ||
| Q4 24 | $-1.95 | $13.33 | ||
| Q3 24 | $-3.08 | — | ||
| Q2 24 | $-2.52 | $-0.55 | ||
| Q1 24 | $-3.04 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $3.5B |
| 总债务越低越好 | $44.7M | — |
| 股东权益账面价值 | $-271.1M | $7.3B |
| 总资产 | $226.8M | $8.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AGENARGX
| Q4 25 | $3.0M | $3.5B | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $9.5M | $2.1B | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $40.4M | $1.5B | ||
| Q3 24 | $44.8M | — | ||
| Q2 24 | $93.7M | $1.4B | ||
| Q1 24 | $52.9M | — |
总债务AGENARGX
| Q4 25 | $44.7M | — | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益AGENARGX
| Q4 25 | $-271.1M | $7.3B | ||
| Q3 25 | $-274.1M | — | ||
| Q2 25 | $-354.6M | $6.1B | ||
| Q1 25 | $-341.8M | — | ||
| Q4 24 | $-326.4M | $5.5B | ||
| Q3 24 | $-292.3M | — | ||
| Q2 24 | $-241.3M | $4.3B | ||
| Q1 24 | $-201.4M | — |
总资产AGENARGX
| Q4 25 | $226.8M | $8.7B | ||
| Q3 25 | $233.9M | — | ||
| Q2 25 | $185.2M | $7.2B | ||
| Q1 25 | $200.2M | — | ||
| Q4 24 | $226.3M | $6.2B | ||
| Q3 24 | $238.5M | — | ||
| Q2 24 | $292.4M | $4.8B | ||
| Q1 24 | $256.6M | — |
负债/权益比AGENARGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | — | $322.4M |
| 自由现金流率自由现金流/营收 | — | 13.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | — | $594.5M |
8季度趋势，按日历期对齐
经营现金流AGENARGX
| Q4 25 | $-16.6M | $323.3M | ||
| Q3 25 | $-14.7M | — | ||
| Q2 25 | $-20.2M | $361.8M | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $41.9M | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.2M | $-124.7M | ||
| Q1 24 | $-38.2M | — |
自由现金流AGENARGX
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | $356.6M | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | $40.9M | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | $-125.5M | ||
| Q1 24 | $-38.2M | — |
自由现金流率AGENARGX
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | 20.1% | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | 3.0% | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | -13.9% | ||
| Q1 24 | -136.5% | — |
资本支出强度AGENARGX
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | 0.1% | ||
| Q1 24 | 0.1% | — |
现金转化率AGENARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
